Breaking News Instant updates and real-time market news.

RVNC

Revance

$20.60

0.1 (0.49%)

16:48
01/18/17
01/18
16:48
01/18/17
16:48

Revance to present RT002 data at January conference, says highlights efficacy

Revance Therapeutics announced presentations of clinical data for DaxibotulinumtoxinA Injectable, or RT002, at the TOXINS 2017 conference January 18-21. The presentations include final data from the Phase 2 BELMONT trial and interim results from a separate Phase 2 study of RT002 in isolated cervical dystonia. "These presentations highlight the safety, efficacy and duration-of-effect results for RT002 injectable from prior studies in both low and high dose indications. We are excited by the prospects of developing a next-generation neurotoxin with an improved safety profile, enhanced treatment effectiveness and long duration, whether for facial aesthetics, acute conditions or chronic disease states. We look forward to reporting results from four ongoing RT002 clinical trials in 2017, including the two SAKURA Phase 3 pivotal trials in glabellar lines, the final results for the Phase 2 trial in cervical dystonia and topline results from a Phase 2 trial for plantar fasciitis," remarked CEO Dan Browne.

RVNC Revance
$20.60

0.1 (0.49%)

06/14/16
RHCO
06/14/16
NO CHANGE
RHCO
Revance price target lowered to $22 from $46 at SunTrust
SunTrust cut its price target on Revance after the company discontinued its RT001 topical development program for lateral canthal lines and excessive sweating due to negative Ph-3 REALISE-1 data. The firm notes that the company is still working on a number of additional treatments. It keeps a Buy rating on the shares.
06/14/16
COWN
06/14/16
NO CHANGE
COWN
Outperform
Revance shares defended at Cowen
06/14/16
COWN
06/14/16
NO CHANGE
Target $55
COWN
Outperform
Revance key value driver remains RT002, says Cowen
Cowen analyst Ken Cacciatore said he shares in the disappointment that Revance's RT001 program is not moving forward, but adds that he believes expectations were low and that investor focus had already shifted, and remains fixed, on the injectable RT002 program, which is the company's key value driver. Cacciatore, who still thinks that RT002 could become a $1B+ product, maintains an Outperform rating and $55 price target on Revance shares, which are down 22% to $14.30 in morning trading.
11/29/16
AGIS
11/29/16
INITIATION
Target $28
AGIS
Buy
Revance initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Revance with a Buy and a $28 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.